Similar to these findings in patients with IGT or type 2 diabetes, we show that shorter term (28 days) treatment of dysmetabolic monkeys with pioglitazone (3 mg kg-1 day-1) increases insulin-stimulated Rd by 62% and enhanced insulin-mediated suppression of EGP by 15%. The gene discussed is INS; the disease is type 2 diabetes mellitus.